HRP20201831T1 - Optimizirani promoter rpe65 i kodirajuće sekvence - Google Patents
Optimizirani promoter rpe65 i kodirajuće sekvence Download PDFInfo
- Publication number
- HRP20201831T1 HRP20201831T1 HRP20201831TT HRP20201831T HRP20201831T1 HR P20201831 T1 HRP20201831 T1 HR P20201831T1 HR P20201831T T HRP20201831T T HR P20201831TT HR P20201831 T HRP20201831 T HR P20201831T HR P20201831 T1 HRP20201831 T1 HR P20201831T1
- Authority
- HR
- Croatia
- Prior art keywords
- sequence
- vector
- rpe
- seq
- specific promoter
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01064—Retinoid isomerohydrolase (3.1.1.64)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Eye Examination Apparatus (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1502137.1A GB201502137D0 (en) | 2015-02-09 | 2015-02-09 | Treatment |
| PCT/GB2016/050289 WO2016128722A1 (en) | 2015-02-09 | 2016-02-08 | Optimized rpe65 promoter and coding sequences |
| EP16703850.4A EP3256169B1 (en) | 2015-02-09 | 2016-02-08 | Optimized rpe65 promoter and coding sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201831T1 true HRP20201831T1 (hr) | 2021-01-08 |
Family
ID=52746363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201831TT HRP20201831T1 (hr) | 2015-02-09 | 2016-02-08 | Optimizirani promoter rpe65 i kodirajuće sekvence |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10568973B2 (enExample) |
| EP (2) | EP3769790A1 (enExample) |
| JP (1) | JP6963503B2 (enExample) |
| CN (1) | CN107429252B (enExample) |
| AU (1) | AU2016217654B2 (enExample) |
| BR (1) | BR112017017060A2 (enExample) |
| CA (1) | CA2975850C (enExample) |
| CY (1) | CY1123947T1 (enExample) |
| DK (1) | DK3256169T3 (enExample) |
| ES (1) | ES2830030T3 (enExample) |
| GB (1) | GB201502137D0 (enExample) |
| HR (1) | HRP20201831T1 (enExample) |
| HU (1) | HUE052407T2 (enExample) |
| IL (2) | IL287142B2 (enExample) |
| LT (1) | LT3256169T (enExample) |
| MX (2) | MX383316B (enExample) |
| PH (1) | PH12017501430A1 (enExample) |
| PL (1) | PL3256169T3 (enExample) |
| PT (1) | PT3256169T (enExample) |
| RS (1) | RS61079B1 (enExample) |
| SG (1) | SG11201706520UA (enExample) |
| SI (1) | SI3256169T1 (enExample) |
| SM (1) | SMT202000655T1 (enExample) |
| WO (1) | WO2016128722A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201502137D0 (en) * | 2015-02-09 | 2015-03-25 | Ucl Business Plc | Treatment |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| CA3022386A1 (en) * | 2016-04-28 | 2017-11-02 | Spark Therapeutics, Inc. | Relative potency assay for viral vector encoding isomerohydrolases |
| US11591615B2 (en) * | 2017-11-30 | 2023-02-28 | Friedrich Miescher Institute For Biomedical Research | SynPIII, a promoter for the specific expression of genes in retinal pigment epithelium |
| CN111118017B (zh) * | 2018-11-01 | 2023-10-03 | 上海朗昇生物科技有限公司 | 治疗Leber先天性黑蒙症的载体及其应用 |
| CN113795575A (zh) | 2019-02-04 | 2021-12-14 | 自由行疗法有限公司 | 多核苷酸 |
| WO2021055760A1 (en) * | 2019-09-18 | 2021-03-25 | Intergalactic Therapeutics, Inc. | Synthetic dna vectors and methods of use |
| GB202002202D0 (en) | 2020-02-18 | 2020-04-01 | Ucl Business Plc | Gene therapy |
| CN113952471A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| JP2023535232A (ja) * | 2020-07-21 | 2023-08-16 | インスピラール リミテッド | 眼疾患の処置のための組成物および方法 |
| CN111826378B (zh) * | 2020-08-05 | 2022-05-27 | 武汉纽福斯生物科技有限公司 | 一种编码人受体酪氨酸激酶Mer的核苷酸序列及其应用 |
| CN112522292B (zh) * | 2020-10-29 | 2023-05-02 | 南京启真基因工程有限公司 | 一种用于构建先天性黑蒙症克隆猪核供体细胞的CRISPR/Cas9系统及其应用 |
| CN115997012B (zh) * | 2021-09-06 | 2024-03-08 | 辉大(上海)生物科技有限公司 | Rpe65相关眼睛疾病和障碍的治疗 |
| EP4646212A1 (en) * | 2023-01-05 | 2025-11-12 | Opus Genetics, Inc. | Gene therapy for ocular disease |
| CN116898991A (zh) * | 2023-06-20 | 2023-10-20 | 浙江大学 | 一种可用于活体的可视化的神经活动状态评估方法及工具病毒载体 |
| CN117018235A (zh) * | 2023-06-20 | 2023-11-10 | 浙江大学 | 一种可用于活体的可视化神经环路的方法及工具病毒载体 |
| WO2026150224A1 (en) | 2024-12-30 | 2026-07-16 | MeiraGTx Ocular UK Limited | Modified adeno-associated virus (aav) viral capsid proteins and methods of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4819683B2 (ja) * | 2004-08-06 | 2011-11-24 | 一般財団法人化学及血清療法研究所 | 酵母プロモーター |
| US7740836B2 (en) | 2006-05-03 | 2010-06-22 | Fondazione Telethon | Methods and compositions for recovering or improving visual function |
| US20100081707A1 (en) * | 2008-02-21 | 2010-04-01 | Ali Robin R | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
| HUE044089T2 (hu) * | 2011-07-18 | 2019-09-30 | Inst Res Biomedicine | Neutralizáló anti-influenza A antitestek és alkalmazásaik |
| US9163259B2 (en) | 2012-05-04 | 2015-10-20 | Novartis Ag | Viral vectors for the treatment of retinal dystrophy |
| TWI698240B (zh) | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| GB201502137D0 (en) * | 2015-02-09 | 2015-03-25 | Ucl Business Plc | Treatment |
| GB202002073D0 (en) * | 2020-02-14 | 2020-04-01 | Ucl Business Ltd | Horizontal cells |
| GB202002202D0 (en) * | 2020-02-18 | 2020-04-01 | Ucl Business Plc | Gene therapy |
-
2015
- 2015-02-09 GB GBGB1502137.1A patent/GB201502137D0/en not_active Ceased
-
2016
- 2016-02-08 ES ES16703850T patent/ES2830030T3/es active Active
- 2016-02-08 BR BR112017017060-4A patent/BR112017017060A2/pt active Search and Examination
- 2016-02-08 PT PT167038504T patent/PT3256169T/pt unknown
- 2016-02-08 IL IL287142A patent/IL287142B2/en unknown
- 2016-02-08 MX MX2017010292A patent/MX383316B/es unknown
- 2016-02-08 EP EP20193488.2A patent/EP3769790A1/en active Pending
- 2016-02-08 JP JP2017541749A patent/JP6963503B2/ja active Active
- 2016-02-08 HU HUE16703850A patent/HUE052407T2/hu unknown
- 2016-02-08 CN CN201680020425.6A patent/CN107429252B/zh active Active
- 2016-02-08 HR HRP20201831TT patent/HRP20201831T1/hr unknown
- 2016-02-08 LT LTEP16703850.4T patent/LT3256169T/lt unknown
- 2016-02-08 AU AU2016217654A patent/AU2016217654B2/en active Active
- 2016-02-08 EP EP16703850.4A patent/EP3256169B1/en active Active
- 2016-02-08 SG SG11201706520UA patent/SG11201706520UA/en unknown
- 2016-02-08 CA CA2975850A patent/CA2975850C/en active Active
- 2016-02-08 US US15/549,549 patent/US10568973B2/en active Active
- 2016-02-08 SM SM20200655T patent/SMT202000655T1/it unknown
- 2016-02-08 PL PL16703850T patent/PL3256169T3/pl unknown
- 2016-02-08 SI SI201630984T patent/SI3256169T1/sl unknown
- 2016-02-08 RS RS20201400A patent/RS61079B1/sr unknown
- 2016-02-08 WO PCT/GB2016/050289 patent/WO2016128722A1/en not_active Ceased
- 2016-02-08 DK DK16703850.4T patent/DK3256169T3/da active
-
2017
- 2017-08-08 IL IL253915A patent/IL253915B/en unknown
- 2017-08-09 PH PH12017501430A patent/PH12017501430A1/en unknown
- 2017-08-09 MX MX2021006762A patent/MX2021006762A/es unknown
-
2020
- 2020-02-20 US US16/796,439 patent/US11969478B2/en active Active
- 2020-11-26 CY CY20201101129T patent/CY1123947T1/el unknown
-
2024
- 2024-04-25 US US18/646,126 patent/US20240293580A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510620A5 (enExample) | ||
| PH12020550706A1 (en) | Adeno-associated virus variant capsids and use for inhibiting angiogenesis | |
| JP2023052541A (ja) | 血管系を通過する遺伝子移入の方法および組成物 | |
| HRP20192141T1 (hr) | Genska terapija za retinitis pigmentosa | |
| JP2017518271A5 (enExample) | ||
| CN111727243A (zh) | 用于跨越血-脑屏障递送病毒载体的方法和组合物 | |
| JP2020528734A5 (enExample) | ||
| HRP20240580T1 (hr) | ISPORUKA ADENO-POVEZANIM VIRUSNIM VEKTOROM β-SARKOGLIKANA I MIKRORNA-29 I LIJEČENJE MIŠIĆNE DISTROFIJE | |
| JP2014512171A5 (enExample) | ||
| RU2013151885A (ru) | Вирионы аденоассоциированного вируса с вариантным капсидом и способы их использования | |
| JP2019521696A5 (enExample) | ||
| HRP20241180T1 (hr) | Modificirani faktor ix, te pripravci, postupci i upotreba za prijenos gena u stanice, organe i tkiva | |
| HRP20230522T1 (hr) | Isporuka adeno-povezanog virusnog vektora mišićno specifičnog mikrodistrofina za liječenje mišićne distrofije | |
| HRP20241483T1 (hr) | Sastavi i postupci za liječenje poremećaja mrežnice | |
| IL292999A (en) | Compositions and methods of treating amyotrophic lateral sclerosis (als) | |
| JP2014507145A (ja) | 改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法 | |
| RU2018132517A (ru) | Aav-idua вектор для лечения ассоциированной с mps i слепоты | |
| HRP20201544T1 (hr) | Pripravci korisni u liječenju nedostatka ornitinske transkarbamilaze (otc) | |
| HRP20201324T1 (hr) | Vektori aav koji sadrže faktor viii koji kodira gen | |
| IL262852B1 (en) | Treatment of complement-mediated disorders | |
| JP2017529395A5 (enExample) | ||
| CN117535247A (zh) | 合理的多倍体腺相关病毒载体及其制造和使用方法 | |
| MY204271A (en) | Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies | |
| IL321380A (en) | Adeno-associated viral vectors for the treatment of best disease | |
| JP2024515626A (ja) | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン |